Tenax Therapeutics receives US patent for IV levosimendan in PH-HFpEF, expiring Dec 2040

TENAX THERAPEUTICS, INC.

U.S. Patent No. 11,607,412 covers IV levosimendan for pulmonary hypertension with HFpEF.
Patent protection extends until December 2040, strengthening IP for levosimendan.
No FDA-approved treatments exist for PH-HFpEF, which affects >1.6M North Americans.
Levosimendan combines K+ATP channel activation and Ca++ sensitization, distinct MoA.
HELP Study showed 29-meter improvement in 6-minute walk distance vs placebo (p=0.03).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.